EFC16033 & EFC16033 Actigraphy (Gemini) A biological drug to treat relapsing Multiple Sclerosis (RMS)
This study evaluates the safety and effectiveness of SAR442168 compared to teriflunominde (Aubagio).
This trial is not accepting new patients.
The purpose of this study is to assess the efficacy and safety of the study drug SAR442168 compared with teriflunomide (Aubagio) in participants with relapsing Multiple Sclerosis (RMS)
Basic Enrollment Criteria:
- Age 18-55 years old, Male & Female
- Willing to comply with study visits and requirements
Study Length:
- approximately 3 years